Nicotibine (Isoniazid)

Isoniazid inhibits the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall. By blocking the enzyme InhA (enoyl‑ACP reductase), it prevents cell‑wall formation, leading to bacterial death in actively replicating Mycobacterium tuberculosis organisms.

The dosage of isoniazid is individualized by the prescribing clinician based on patient age, weight, liver function, and treatment regimen. The prescriber determines the appropriate strength, frequency, and duration in accordance with national TB guidelines.

Safety data are limited; isoniazid is classified as a pregnancy‑category D drug in many regions, indicating potential risk. It may be used during pregnancy only when the expected benefit outweighs the risk, and pyridoxine supplementation is recommended. Breastfeeding decisions should be made with a healthcare professional.

To request Nicotibine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isoniazid is one of the core first‑line agents for TB because of its potent bactericidal activity, oral availability, and low cost. Compared with alternatives such as rifampicin or ethambutol, it has a distinct mechanism targeting mycolic‑acid synthesis, but it carries a higher risk of hepatotoxicity and peripheral neuropathy, requiring monitoring and pyridoxine supplementation.

Nicotibine should be stored at ambient temperature, preferably below 25 °C, in its original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Nicotibine is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily or as directed—must follow the prescriber’s instructions and be part of a complete anti‑TB regimen.

The most serious adverse reactions include hepatotoxicity, which can progress to severe hepatitis or liver failure, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Neurological toxicity, manifested as peripheral neuropathy or seizures, can also occur, especially in patients with pre‑existing risk factors.

Individuals with known hypersensitivity to isoniazid or any component of the formulation should avoid Nicotibine. Patients with severe liver disease, active hepatitis, or those who cannot safely receive pyridoxine supplementation should be evaluated carefully before use.